Innoviva Chairman George Bickerstaff to retire at 2023 Annual Meeting; board to shrink to 6

Innoviva, Inc.

George Bickerstaff, III, Chairman since 2020, will not stand for reelection; departure is not due to any disagreement.
Board size to be reduced from seven to six members immediately after the 2023 Annual Meeting.
New Chairperson will be elected by the Board following the meeting; no successor named yet.
Bickerstaff cited focus on other professional and philanthropic pursuits, including role at International Vaccine Institute.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

George Bickerstaff, III

Chairman of the Board

INVA · Innoviva, Inc.

Filed: May 1, 2023, 7:59 PM ET

George Bickerstaff, III, Chairman of the Board, notified the Board of Directors (the “Board”) of Innoviva, Inc. that he will retire from the Board, including the committees of the Board of the Company of which he is a member, at the end of his current term at the 2023 Annual Meeting of shareholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

George Bickerstaff, III departed as Chairman of the Board at Innoviva, Inc..

Action: retire
Role: Chairman of the Board

Exact text from the filing

George Bickerstaff, III, Chairman of the Board, notified the Board of Directors (the “Board”) of Innoviva, Inc. that he will retire from the Board, including the committees of the Board of the Company of which he is a member, at the end of his current term at the 2023 Annual Meeting of shareholders.

View on SEC.gov

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-128122

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.